HOME >> MEDICINE >> NEWS
12-month study demonstrated tolerability and efficacy of Daytrana

SAN DIEGO MAY 23, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that DAYTRANATM (methylphenidate transdermal system), the first and only non-oral medication approved for treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 to 12 years, provided significant improvement in symptom control and tolerability, according to results of a 12-month open-label study presented at the American Psychiatric Association (APA) annual meeting in San Diego.

"We documented that children with ADHD experienced effective ADHD treatment with use of DAYTRANA for 12 months, sustaining the improvements in their ability to maintain focus and concentration," said investigator Oscar Bukstein, M.D., M.P.H ,Associate Professor of Psychiatry, University of Pittsburgh School of Medicine. "More importantly, Daytrana maintained a favorable safety profile, meeting the study's primary endpoint, and demonstrating an incidence of adverse events that is consistent with previous trials and other stimulants in this class."

Shire's DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. DAYTRANA is available in four dosage strengths 10 mg, 15 mg, 20 mg and 30 mg all designed for once-daily use. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because DAYTRANA is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired or to help manage the potential for late-day side effects.

Bukstein added, "DAYTRANA's novel patch delivery system offers physicians and parents of children with ADHD a convenient, non-oral option to individualize ADHD treatment to meet their children's changing schedules."

This study was an open-label extension of four clinical trials. T
'"/>

Contact: Marion E. Glick
212-601-8273
Porter Novelli
23-May-2007


Page: 1 2 3

Related medicine news :

1. $1.5 billion needed to ensure 12-month stockpile of pediatric vaccines
2. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
3. Penn study finds pro-death proteins required to regulate healthy immune function
4. New study shows promise in reducing surgical risks associated with surgical bleeding
5. New study counts the economic cost of persistent pain in Australia
6. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
7. Most seniors now have drug coverage, U-M study shows
8. To gain muscle and lose fat, drink milk: study
9. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
10. Even older women at high risk have little interest in being tested for HIV, study finds
11. Metabolic study in mice could lead to good cholesterol boosters

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: month study demonstrated tolerability and efficacy Daytrana

(Date:8/5/2015)... ... , ... The June 6 opening of Chicago’s new elevated trail, the 606, has been getting ... a group of walkers at Sedgebrook senior living community in Lincolnshire. Known as the ... preserves and twice per month to more distant places. When they read about the ...
(Date:8/5/2015)... ... 05, 2015 , ... What language does a body speak? "Body Language ... idioms and other expressions that contain the name of a body part. , The ... about 2,000 such idioms, words, and expressions, for example, “back against the wall,” “brainstorming,” ...
(Date:8/5/2015)... ... August 05, 2015 , ... ... filed in the testosterone multidistrict litigation known as Testosterone Replacement Therapy Products Liability ... Northern District of Illinois. The Motion to Dismiss was filed by the defendants, ...
(Date:8/5/2015)... ... ... Wildflower Seed & Tool Company ” was featured on NewsWatch as part of its ... impact in their industry. Susan Bridges, a reporter for NewsWatch and a business expert, ... designed for women. , With overweight gardening tools that seem like they’re designed for ...
(Date:8/5/2015)... ... ... Available in select spas and at http://www.lespausa.com , Phytomer ... oils. A perfect complement to Phytomer’s top selling product, ROSÉE VISAGE Cleansing Toning ... soothing properties. Formulated as a light and comfortable dry oil, it quickly penetrates the ...
Breaking Medicine News(10 mins):Health News:Sedgebrook Trailblazers Tread New Ground on Chicago’s New 606 Path 2Health News:Sedgebrook Trailblazers Tread New Ground on Chicago’s New 606 Path 3Health News:Harvard Medical Professor Dr. Per-Olof Hasselgren Pens Unique Book Using Body Part Idioms 2Health News:Testosterone Lawsuit News: Defendants Push Back Against RICO Claim 2Health News:Testosterone Lawsuit News: Defendants Push Back Against RICO Claim 3Health News:Testosterone Lawsuit News: Defendants Push Back Against RICO Claim 4Health News:Wildflower Seed & Tool Company Design Gardening Tools Specifically for Women 2Health News:Phytomer launches ROSÉE SOIN Radiance Replenishing Oil 2Health News:Phytomer launches ROSÉE SOIN Radiance Replenishing Oil 3Health News:Phytomer launches ROSÉE SOIN Radiance Replenishing Oil 4
(Date:8/4/2015)... SEATTLE , Aug. 4, 2015  Dr. ... Institute states the potential FDA approval of flibanserin, ... sets women and the treatment of decreased female ... women has many root causes and addressing libido ... is dangerous. ...
(Date:8/4/2015)... Pharmaceuticals, Inc. (Nasdaq: ISIS ) today reported net ... three and six months ended June 30, 2015, respectively, ... $43.4 million for the same periods in 2014. Isis, ... more than $90 million of revenue Isis earned in ... Bayer to license  ISIS-FXI Rx .  Isis increased its ...
(Date:8/4/2015)... 2015  Intec Pharma Ltd. (the "Company") (NASDAQ: ... developing drugs based on its proprietary Accordion Pill platform ... offering in the United States ... to the public of $6.00 per ordinary share, before ... are being offered by the Company.  In addition, the ...
Breaking Medicine Technology:Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5Isis Reports Financial Results And Highlights For Second Quarter 2015 2Isis Reports Financial Results And Highlights For Second Quarter 2015 3Isis Reports Financial Results And Highlights For Second Quarter 2015 4Isis Reports Financial Results And Highlights For Second Quarter 2015 5Isis Reports Financial Results And Highlights For Second Quarter 2015 6Isis Reports Financial Results And Highlights For Second Quarter 2015 7Isis Reports Financial Results And Highlights For Second Quarter 2015 8Isis Reports Financial Results And Highlights For Second Quarter 2015 9Isis Reports Financial Results And Highlights For Second Quarter 2015 10Isis Reports Financial Results And Highlights For Second Quarter 2015 11Isis Reports Financial Results And Highlights For Second Quarter 2015 12Isis Reports Financial Results And Highlights For Second Quarter 2015 13Isis Reports Financial Results And Highlights For Second Quarter 2015 14Isis Reports Financial Results And Highlights For Second Quarter 2015 15Isis Reports Financial Results And Highlights For Second Quarter 2015 16Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3
Cached News: